Arcoma AB (ARCOMA) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Arcoma AB stock SEK 10.36, price SEK 8.50, upside +21.9%, quality 60 out of 100. Rating: undervalued. Calculated from audited financials with 22 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range kr 6.50 – kr 20.20 · fair‑value band kr 7.99 – kr 12.72 · the kr 8.50 price screens below the kr 10.36 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow Arcoma in your weekly email
Every Wednesday you see whether Arcoma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Arcoma AB develops, produces, and provides radiology solutions and digital x-ray systems in Sweden and internationally. The company offers solutions for x-ray systems covering radiological applications and general, eneral, muscle/skeleton, thoratic, pediatric, and trauma/resus clinics.
Show moreShow less
It also provides x-ray detectors; video bank; and accessories for x-ray equipment comprising live camera, advanced remote control, form pad, hand control, compression belt, lateral cassette/detector holder, foot control, lateral armrest, patient handgrip, mattress, scatter correction software, battery charger, battery pack, and stitching screen.
It manufactures x-ray equipment under the Canon and Konica Minolta brand name. The company sells its products through resellers and OEM customers. Arcoma AB was incorporated in 1990 and is based in Växjö, Sweden.
Stock analysis
Arcoma AB (ARCOMA) currently trades at kr 8.50, while our model-based Fair Value estimate is kr 10.36, implying the stock looks roughly 18% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of kr 13.75 per share, and 15 of the 22 models we run sit above the kr 8.50 price.
Bear case: the Asset-Based group reads lowest at kr 3.82, and 7 of the 22 models stay below the price. Data coverage for this calculation is low.
Scenario range: kr 7.99 (bear) to kr 12.72 (bull), the price of kr 8.50 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Arcoma AB reported revenue of 131M SEK in FY2025 versus 117M SEK in FY2021, a compound +2.8%/yr. Reported net income was 5.0M SEK in FY2025.
Key figures
Market cap 122M SEK (≈ $12.3M) Micro · P/E ratio 24.3 · P/S ratio 0.98 · EPS (TTM) kr 0.3500 · Net margin 3.9% · Return on equity 6.4% · Return on assets (EBIT) 5.1% (5-year average) · Operating margin 10.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 41 out of 100 (low confidence).
What moves the price
The share trades about 13% below its 52-week high and 23% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at 22%, ARCOMA screens cheaper than that median.
Fair Value models
Bearkr 7.99Fair Value kr 10.36Bullkr 12.72
Price kr 8.50 · Upside +21.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (kr 0.3001 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.56/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−16.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.2%
Start year 2020 (pandemic). Over 10 years: +0.6% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+33.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+33.2%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.2.2% vs 34.0%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.2% → 7%
2025 sits 83% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−12.4%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Sweden: IMF forecast 2.0% a year to 2030, 2.9% from 2016 to 2025) that is about −14.1% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks
Beats the industry median on 9/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score60 · Above median
Fair Value upside+21.9% · Top 25%
Profitability
Return on equity (12 months)6.4% · Above median
Return on assets5.2% · Above median
Net margin (12 months)3.9% · Below median
Operating margin (12 months)10.7% · Above median
Growth and dividend
Revenue growth (quarter YoY)−10.1% · Bottom 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Arcoma AB Fair Value". https://www.fairvalue-calculator.com/stock/ARCOMA
Frequently asked questions
Is Arcoma AB (ARCOMA) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of kr 10.36 versus a price of kr 8.50, about +22% upside (undervalued).
What is the fair value of ARCOMA?
Our model-based fair value for Arcoma AB is kr 10.36 (as of Nov 7, 2026), built from audited fundamentals. The current price: kr 8.50.
What is the quality score of ARCOMA?
Arcoma AB has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Arcoma AB (ARCOMA)?
Our model-based price target is the fair value of kr 10.36 (as of Nov 7, 2026) from 22 valuation models. Cautious scenario kr 7.99, optimistic scenario kr 12.72. It is a calculation from audited fundamentals, not an analyst target.
What is the Arcoma AB stock forecast for 2026?
Our models put fair value at kr 10.36, about +22% upside versus a price of kr 8.50 (undervalued). Cautious scenario kr 7.99, optimistic scenario kr 12.72. The calculation is refreshed regularly with new filings.
What is the revenue of Arcoma AB (ARCOMA)?
Arcoma AB reported trailing-twelve-month revenue of about 124M SEK (latest available figure, as of Nov 7, 2026).
What growth is priced into Arcoma AB (ARCOMA)?
For today's price to be fair in a discounted-cash-flow model, Arcoma AB would have to grow free cash flow by -12.4 % per year for five years (discount rate 8.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +2.2 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of ARCOMA use?
Our models discount Arcoma AB at 8.8 %: a base by market capitalisation (nano), damped by beta 0.70, country premium for Sweden. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Arcoma AB that is -12.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.8 %) and the same formula as our fair value.
How much growth has Arcoma AB (ARCOMA) delivered so far?
Over the past 5 years revenue at Arcoma AB grew +2.2 % a year. The price currently implies free-cash-flow growth of -12.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Arcoma AB (ARCOMA) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Arcoma AB (-12.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Arcoma AB (ARCOMA)?
The free-cash-flow yield on the price is 10.77 %: that much free cash flow Arcoma AB produces per unit of market value. When it exceeds the discount rate of our models (8.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Arcoma AB (ARCOMA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Arcoma AB it is kr 10.36 per share (as of Nov 7, 2026), against a price of kr 8.50. It is the blended result of 22 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Arcoma AB stock overvalued or undervalued in 2026?
As of Nov 7, 2026, ARCOMA trades below its calculated fair value: price kr 8.50, fair value kr 10.36, a gap of about +22% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ARCOMA?
No. The price is what the market pays today (kr 8.50); the fair value is what the company's own numbers justify (kr 10.36). For Arcoma AB the two are kr 1.86 per share apart. That gap is exactly why we show both numbers side by side.
How much is Arcoma AB worth?
The market values Arcoma AB at about 122M SEK (market capitalisation, as of Nov 7, 2026). Per share that is kr 8.50; our models calculate a fair value of kr 10.36 per share.
What do the bullish and bearish scenarios say about ARCOMA?
Our models span a range for Arcoma AB: cautious scenario kr 7.99, base kr 10.36, optimistic kr 12.72 per share (as of Nov 7, 2026, price kr 8.50). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ARCOMA?
Arcoma AB trades at a price-to-earnings ratio of 24.3 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 10.36 is built from several models across several years. Median P/E at fiscal year-end, 6 fiscal years (2019 to 2025), reported earnings: 39.6. Other multiples: P/B 1.6, P/S 1.0, EV/EBITDA 20.9.
How solid is the balance sheet of Arcoma AB (ARCOMA)?
Balance-sheet figures for Arcoma AB (as of Nov 7, 2026): return on equity 6.4%. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is ARCOMA from its 52-week high?
Arcoma AB trades at kr 8.50, about 13% below its 52-week high of kr 9.80 and 23% above the low of kr 6.92 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of kr 10.36 is for.
Which stocks are comparable to Arcoma AB?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Arcoma AB stock attractive at the current price?
The data as of Nov 7, 2026: price kr 8.50, calculated fair value kr 10.36 (+22%), Quality Score 60/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ARCOMA calculated?
We run Arcoma AB through 22 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of kr 10.36 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Arcoma AB currently trades 18% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Arcoma AB (ARCOMA)?
The closing price on Nov 6, 2026 was kr 8.50. Our model-based fair value is kr 10.36, about +22% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Arcoma AB right now?
Solid quality (60/100) at a price below fair value, the discount is the argument here, not the business quality. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Arcoma AB
How large is the market capitalisation of Arcoma AB (ARCOMA)?
The market capitalisation of Arcoma AB is 122M SEK (≈ $12.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Arcoma AB (ARCOMA)?
The price-to-sales ratio of Arcoma AB is 0.98 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Arcoma AB (ARCOMA)?
Earnings per share at Arcoma AB are kr 0.3500 (price ÷ EPS = P/E 24.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Arcoma AB (ARCOMA)?
The net margin of Arcoma AB is 3.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Arcoma AB (ARCOMA)?
The return on equity (ROE) of Arcoma AB is 6.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Arcoma AB (ARCOMA)?
On an EBIT basis the return on assets of Arcoma AB is 5.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Arcoma AB (ARCOMA)?
The operating margin of Arcoma AB is 10.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Arcoma AB (ARCOMA)?
Revenue at Arcoma AB is growing −10.1% versus a year earlier (3y avg +1.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Arcoma AB (ARCOMA)?
Earnings per share at Arcoma AB are growing +45.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Arcoma AB (ARCOMA) hold?
Arcoma AB holds more cash than debt, 35.3M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Arcoma AB in the live analysis
One click puts Arcoma AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 7, 2026